Separate names with a comma.
Gene therapy is one avenue that's being explored. The two main companies (that I'm aware of) in this space are Decibel Therapeutics and Akouos....
They did a one-year follow up on the Phase 1/2 trial participants and the effects at 90 days had significantly lessened. They did a similar long...
He was asked about this on Twitter and replied "No plan to do that. Not convinced that drug delivery was FX-322’s only challenge". I found this...
Elsewhere on Twitter he says (in regards to a hearing drug) "We’ve been testing a wide range of approaches in the lab. Might have something ready...
As I said in my previous post, their current drug candidate, SPT-2101, is dexamethasone - which is what Otonomy's Ovitidex was. If SPT-2101 shows...
I unfortunately can't find any info on it. I did find this press release though, which talks about the Phase 1 and Phase 2 studies of SPT-2101....
He said this in a thread where he discussed why he thought FX-322 failed. I wonder if his company will try to acquire the rights to that too. It'd...
They did, but they didn't expect a response from them, they just did them for safety reasons. Here's what they told me when I emailed them back in...
My guess is they'll take a close look at all of the data they're given to see if they think BDNF is viable to move forward with. I assume they're...
I don't know, the liquidation has been moving along though. I honestly don't expect us to hear much for a while. I still don't understand why one...
Two months ago Frequency Therapeutics did a story with CBS that featured a former trial patient saying they got "84%" of their hearing back. It's...
The cancelling of FX-345 was the only thing that shocked me with today's press release. I had kind of expected FX-322 to fail again. The data from...
Around 2 weeks ago, David Lucchino, the CEO of Frequency Therapeutics, made 2 retweets which I thought were odd and with hindsight seem even...
The news is out. Looks like it's bad. "The study, which enrolled 142 people with either sudden or noise-induced sensorineural hearing loss,...
As an aside, Michelle Solly, a biotech analyst on Twitter, did a really good write-up on Frequency Therapeutics 2 years ago, right before the...
